Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company dedicated to the discovery, development, and commercialization of proprietary cancer therapies. Founded in 2012 and headquartered in Shelton, Connecticut, the company's mission is to extend and improve the quality of life for patients by developing first-in-class cancer drugs that reduce tumors with minimal side effects, while simultaneously activating the patient's immune system to combat the disease.

The company leverages its proprietary DfuseRx℠ discovery platform to create patented anti-cancer product candidates. Its lead investigational product, INT230-6, is designed for direct intratumoral injection. This formulation combines two established anti-cancer cytotoxic agents, cisplatin and vinblastine, with a diffusion and cell penetration enhancer molecule (SHAO). This approach aims to induce localized tumor cell death, generate antigenic sites to stimulate the adaptive immune system, and ultimately eliminate both injected and distant tumors and micrometastases, all while minimizing systemic toxicities. Intensity Therapeutics focuses on solid tumors, with ongoing clinical trials in metastatic sarcoma and triple-negative breast cancer.

Led by Founder, President, CEO, and Chairman Lewis H. Bender, Intensity Therapeutics is publicly traded on NASDAQ under the ticker INTS. Recent notable developments include receiving the Pinnacle Award for Excellence in Healthcare Innovation in April 2026 and strengthening its intellectual property portfolio with a new U.S. patent in March 2026. The company also reported its 2025 year-end financial results and provided a corporate update in March 2026. In February 2026, Intensity Therapeutics executed a 1-for-25 reverse stock split and subsequently regained compliance with Nasdaq's minimum bid price requirement. The company continues to advance its clinical pipeline, including a Phase 3 study (INVINCIBLE-3) for metastatic sarcoma and a Phase 2/3 program (INVINCIBLE-4) for triple-negative breast cancer, with collaborations noted with Merck and Bristol-Myers Squibb.